Scottsdale, Arizona 9/23/2009 2:59:24 AM
News / Business

Manhattan Scientifics Inc. (MHTX.OB) Inks Licensing Agreement with Carpenter Technology

QualityStocks would like to highlight Manhattan Scientifics Inc. (OTCBB: MHTX). The company’s business model capitalizes on inventions and technology from which profits may be earned primarily through licensing. Operations include identifying, developing, patenting, supporting and marketing technical innovations by harvesting top technology talent to bring game-changing technology to the market.

 

In the company’s news yesterday,

 

Manhattan Scientifics Inc. announced an agreement with Carpenter Technology Corp. (NYSE: CRS) in which Carpenter will develop, manufacture and market a new class of high-strength metals under an exclusive license from Manhattan Scientifics and the Los Alamos National Laboratory.

 

“Carpenter continues to forge ahead as the leading developer of stainless steels and specialty alloys,” Anne L. Stevens, Carpenter’s chairman and CEO stated in the press release. “Our relationship with Manhattan Scientifics will ultimately give us new, cutting-edge manufacturing techniques that we can apply to many of our alloys to service an increasing global need for high strength materials.”

 

The noted process utilizes super-strength metals and alloys to produce lower-weight products without costly premiums. The Los Alamos National Laboratory, along with a team of Russian scientists, has developed a new form of titanium metal designed for the healthcare market. The titanium is expected to improve medical prosthetics as it is shown to integrate with bone up to 20 times faster than conventional methods.

 

Manny Tsoupanarias, Manhattan Scientific’s CEO, said Carpenter makes the ideal partner in the metals industry.

 

“Carpenter Technology, a billion dollar multi-national organization, is exactly the kind of manufacturing partner we were looking for to bring our superior ultrafine grain metals to market throughout the world,” Tsoupanarias stated. “The contract will provide quick and sustained revenue to Manhattan Scientifics. Moreover, we anticipate positive cash flow, reliable revenue and profitability during the next 12 months. This is a major breakthrough for our 8,600 shareholders.”

 

Carpenter is also currently reviewing other applications for the titanium, which received FDA-approval for its use in the $2 billion dental implant market. The company views the transportation industry as a possible target because of the need for lighter, more fuel efficient vehicles.

 

Manhattan Scientifics previously partnered with the Los Alamos National Laboratory through an exclusive agreement in which Manhattan Scientific acquired the U.S. license of a family of patents developed by scientists at the laboratory. Yesterday’s announced contract calls for minimum annual payments to Manhattan Scientifics over a four-year period, including royalty payments from gross sales.

 

About QualityStocks

 

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

 

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net 

 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.